Regeneron stock gains FDA approval for Livsayis in gMG
Published on 11/21/2026 at 11:42 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSRegeneron's new neurology milestone
- The FDA approved Livsayis for adults with antibody-positive generalized myasthenia gravis.
- The therapy is Regeneron's first approved siRNA medicine and its first approved neurology treatment.
- Phase 3 results showed sustained improvements in daily function and muscle strength through 24 weeks.
Regeneron received U.S. approval for Livsayis on Wednesday, November 18, 2026, adding a new treatment for adults with antibody-positive generalized myasthenia gravis. The company announced the decision in a Regeneron release.
Approval expands Regeneron's treatment portfolio
Livsayis is the first approved small interfering RNA therapy for generalized myasthenia gravis and Regeneron's first approved siRNA medicine and neurology treatment. The drug is administered under the skin four times a year, or once every three months.
The approval covers adults who test positive for anti-acetylcholine receptor antibodies, the predominant form of the disease. Livsayis reduces circulating complement component 5, a protein involved in the immune response that can damage the connection between nerves and muscles.
Trial results support the regulatory decision
The FDA relied on results from the Phase 3 NIMBLE trial. After 24 weeks, patients receiving Livsayis recorded a 4.5-point improvement in the Myasthenia Gravis-Activities of Daily Living score, compared with 2.2 points for placebo. The corresponding improvements in the Quantitative Myasthenia Gravis score were 4.2 points and 1.5 points.
The company said symptom control was maintained through the dosing interval. The prescribing information includes a boxed warning for serious meningococcal infections, and treatment is available through a restricted risk-management program.
Commercial execution remains the next focus
Regeneron is solely responsible for developing, manufacturing and commercializing Livsayis under its worldwide licensing agreement with Alnylam. A regulatory submission for the treatment is under review in the European Union, with a decision anticipated in the second half of 2027.
Regeneron Pharmaceuticals
- Company: Regeneron Pharmaceuticals, Inc.
- ISIN: US75886F1075
- Nasdaq ticker: REGN
- Key event: FDA approval of Livsayis on November 18, 2026
The US market backdrop is covered in Current market reports.
